Turkey

Sisecam: Growth continues with improved margins

  • Based on latest estimate, we are revising up our 12-mnth TP by 43% to TL14.3, implying 63% upside potential

  • Targeted EBITDA margin revised up to 25% plus from 20% plus by management

  • Glass packaging investment in Hungary might increase capacity by 13%

https://cdn.tellimer.com/providers/badge-ata-invest-bZ2qBXVWtZfl26qH3OLjfMn9TkdTsjoY6bSn27iv.png
Aytunc Uz @ ATA Invest
September 1st, 2021
This is a premium report that requires access to ATA Invest
ATA Invest ATA Invest

Coverage

Turkey

About

ATA Holding is a third-generation family-owned conglomerate, primarily active in financial services, food & retail, technology and rea estate. ATA Group consists of more than 20 companies, with a total consolidated sales figure exceeding US$2.0bn.

Services

Personal solutions
Add-on
This includes investment consultancy, asset management, pension services, and more.
Corporate solutions
Add-on
We offer comprehensive services relating to mergers and acquisitions and privatisation products
Full list of services

Recommendations

Access to recommendations is a Pro feature.

Most Read

1 ∙ Strategy Note ∙ MENA
Iran's telegraphed attack on Israel confirms war is not inevitable
2 ∙ Strategy Note ∙ Global
Policy stimulus capacity in emerging markets after US rate cut hopes pushed out
3 ∙ Strategy Note ∙ Georgia
Georgia protests portend potentially disorderly election in October
4 ∙ Strategy Note ∙ Global
IMF updated forecasts: EM still outpacing DM but low-income EM growth cut
5 ∙ Strategy Note ∙ Global
Peru plunders private pensions again: Reinforces preference for Chile, Colombia

Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.

This research is produced by a third party. The Tellimer team has had no editorial input into the content of the note.